SRT-2104

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
SRT-2104
DrugBank Accession Number
DB12186
Background

SRT2104 has been investigated for the basic science and treatment of Sepsis, PSORIASIS, Atrophy, Muscular, and Diabetes Mellitus, Type 2.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 516.64
Monoisotopic: 516.140216385
Chemical Formula
C26H24N6O2S2
Synonyms
Not Available
External IDs
  • SRT2104

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as aromatic anilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with an aromatic group. They have the general structure RNC(=O)R', where R= benzene, and R = aryl group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Anilides
Direct Parent
Aromatic anilides
Alternative Parents
Phenylimidazoles / 2,4,5-trisubstituted thiazoles / Thiazolecarboxamides / 2-heteroaryl carboxamides / Aralkylamines / Pyridines and derivatives / Morpholines / N-substituted imidazoles / Heteroaromatic compounds / Secondary carboxylic acid amides
show 7 more
Substituents
2,4,5-trisubstituted 1,3-thiazole / 2-heteroaryl carboxamide / 4-phenylimidazole / 5-phenylimidazole / Amine / Amino acid or derivatives / Aralkylamine / Aromatic anilide / Aromatic heteropolycyclic compound / Azacycle
show 25 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
4521NR0J09
CAS number
1093403-33-8
InChI Key
LAMQVIQMVKWXOC-UHFFFAOYSA-N
InChI
InChI=1S/C26H24N6O2S2/c1-17-23(36-25(28-17)18-5-4-8-27-13-18)24(33)29-21-7-3-2-6-20(21)22-15-32-19(16-35-26(32)30-22)14-31-9-11-34-12-10-31/h2-8,13,15-16H,9-12,14H2,1H3,(H,29,33)
IUPAC Name
4-methyl-N-(2-{3-[(morpholin-4-yl)methyl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl)-2-(pyridin-3-yl)-1,3-thiazole-5-carboxamide
SMILES
CC1=C(SC(=N1)C1=CC=CN=C1)C(=O)NC1=CC=CC=C1C1=CN2C(CN3CCOCC3)=CSC2=N1

References

General References
Not Available
PubChem Compound
25108829
PubChem Substance
347828472
ChemSpider
28637794
ZINC
ZINC000043202455

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedOtherType 2 Diabetes Mellitus1
2CompletedTreatmentPsoriasis1
2CompletedTreatmentType 2 Diabetes Mellitus1
1CompletedBasic ScienceChronic Obstructive Pulmonary Disease (COPD)1
1CompletedBasic ScienceHealthy Volunteers (HV) / Type 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0264 mg/mLALOGPS
logP3.79ALOGPS
logP3.29Chemaxon
logS-4.3ALOGPS
pKa (Strongest Acidic)11.2Chemaxon
pKa (Strongest Basic)5.89Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area84.65 Å2Chemaxon
Rotatable Bond Count6Chemaxon
Refractivity163.83 m3·mol-1Chemaxon
Polarizability54.74 Å3Chemaxon
Number of Rings6Chemaxon
Bioavailability1Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-014i-0010090000-41353e11deafb00f3b0e
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-3900110000-1f163e02ba077f9b3e08
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-014i-0130190000-57cff08efa617b2ac695
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0uk9-4394320000-0b4a3d95dccc450dae4b
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-016r-0870940000-1b04d2aced852bf61d1f
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-006x-9628710000-6bb427cf8c541fee06aa
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-237.9891955
predicted
DarkChem Lite v0.1.0
[M-H]-204.26689
predicted
DeepCCS 1.0 (2019)
[M+H]+238.6946955
predicted
DarkChem Lite v0.1.0
[M+H]+206.66245
predicted
DeepCCS 1.0 (2019)
[M+Na]+238.1673955
predicted
DarkChem Lite v0.1.0
[M+Na]+212.57497
predicted
DeepCCS 1.0 (2019)

Drug created at October 20, 2016 21:34 / Updated at June 12, 2020 16:53